Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALLIbrahim Aldoss, Betsy Blunk, Timothy E. O’Connor et al.|Blood Advances|2024Cited by 12
Efficacy and Safety of Brexucabtagene Autoleucel for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Patients Aged 60 and AboveIbrahim N. Muhsen, Kristen M. O'Dwyer, Anjali S. Advani et al.|Blood|2024Cited by 3
KMT2Ar Adversely Impacts Brexucabtagene Autoleucel (Brexu-cel) Outcome in Adults with Relapsed/ Refractory (r/r) B-Cell Acute Lymphoblastic Leukemia.Abdullah Ladha, Caspian Oliai, Virginia Tan et al.|Transplantation and Cellular Therapy|2025Cited by 1
NGS MRD Negativity on Day 28 after Brexu Cel in Adults with R/R ALL Is Associated with Favorable Progression Free SurvivalYannis K. Valtis, Aaron C. Logan, Divya Koura et al.|Transplantation and Cellular Therapy|2025Cited by 0